Saturday, November 15, 2014 3:54:58 PM
Diabetes Analyst: Sanofi CEO's Firing May Spell Trouble for MannKind Afrezza Partnership
By: Adam Feuerstein Follow | 11/04/14 - 01:40 PM EST
MannKind (MNKD) used its quarterly conference call Monday night to tamp down any concerns about the firing of Sanofi (SNY) CEO Chris Viehbacher causing problems for the Afrezza diabetes partnership ahead of the expected first quarter 2015 launch.
Not everyone shares MannKind's confidence. Diabetic Investor's David Kliff, a longtime Afrezza skeptic, believes Viehbacher was the driving force behind the MannKind partnership and pushed the deal against the wishes of others at Sanofi who didn't want anything to do with the inhaled insulin device. Now that Viehbacher is out at Sanofi, Kliff says the Afrezza commercial launch might be in trouble even before it starts.
Kliff, writing today to his subscribers:
With Viehbacher now gone and Sanofi expected to bring in a change agent with diabetes experience it's quite possible that this new person could reexamine the deal and decide it's just not worth the effort, not to mention the capital investment needed. A critical date here is November 20 when the company holds their analyst day, a day which according to MannKind management Afrezza will be big part of, the star of the show so to speak. Many observers believe that Sanofi will announce Viehbacher's replacement as early as this week. Given the timing of all these events it will be interesting to see if the new person, only in charge a short time, makes the first of several changes and knocks Afrezza out if it's starring role.
TRADING TNA AND TZA
http://investorshub.advfn.com/TRADING-TNA-AND-TZA-12981/
Recent MNKD News
- INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions • GlobeNewswire Inc. • 06/22/2024 12:00:00 PM
- Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions • GlobeNewswire Inc. • 06/05/2024 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 01:00:03 AM
- MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix • GlobeNewswire Inc. • 05/29/2024 12:45:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 01:00:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 01:00:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 01:00:19 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 01:00:13 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/21/2024 08:09:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/21/2024 08:07:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2024 01:36:29 AM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM